Genelux Corporation (GNLX)
| Market Cap | 119.90M -2.1% |
| Revenue (ttm) | 8,000 |
| Net Income | -33.58M |
| EPS | -0.85 |
| Shares Out | 44.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250,836 |
| Open | 2.700 |
| Previous Close | 2.650 |
| Day's Range | 2.540 - 2.730 |
| 52-Week Range | 2.290 - 8.535 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 17.50 (+548.15%) |
| Earnings Date | Aug 13, 2026 |
About GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product... [Read more]
Financial Performance
In 2025, Genelux's revenue was $8,000, a change of 0.00% compared to the previous year's $8,000. Losses were -$32.15 million, 7.62% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price target is $17.5, which is an increase of 548.15% from the latest price.
News
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -
Genelux Transcript: AGM 2026
The meeting covered the election of a director and auditor ratification, with both proposals approved. No shareholder questions were received, and final voting results will be filed with the SEC.
Genelux reports Q1 EPS (20c), consensus (19c)
“As we build on our momentum entering 2026, we remain focused on disciplined execution of our registrational program. The randomized Phase 3 OnPrime/GOG-3076 trial remains on track for topline data…
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected...
Genelux Quarterly report: Q1 2026
Genelux has published its Q1 2026 quarterly earnings report on May 7, 2026.
Genelux Earnings release: Q1 2026
Genelux released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Genelux Slides: Corporate presentation
Genelux has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Genelux Proxy statement: Proxy filing
Genelux filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Genelux Proxy statement: Proxy filing
Genelux filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Genelux price target lowered to $20 from $23 at Benchmark
Benchmark lowered the firm’s price target on Genelux (GNLX) to $20 from $23 and keeps a Speculative Buy rating on the shares after adjusting the firm’s sum-of-the-parts analysis for the…
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in r...
Genelux Annual report: Q4 2025
Genelux has published its Q4 2025 annual report on March 19, 2026.
Genelux Earnings release: Q4 2025
Genelux released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Genelux Transcript: Fireside chat
The discussion highlighted Olvi-Vec's potential as a backbone therapy in oncology, showing strong efficacy in platinum-resistant ovarian cancer and promising early results in lung cancer. The company is preparing for commercial launch, expanding indications, and expects pivotal data later this year.
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...
Genelux prices 6.67M shares at $3.00 in underwritten public offering
Genelux (GNLX) Corporation announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of…
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritte...
Genelux announces common stock offering, no amount given
Genelux (GNLX) Corporation announced that it has commenced a proposed underwritten public offering of its common stock. All shares are being offered by Genelux. Lucid Capital Markets is acting as…
Genelux Corporation Announces Proposed Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a propo...
Genelux data update indicates disease early control, says H.C. Wainwright
Genelux (GNLX) reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate and 67% disease control rate in heavily pretreated platinum-relapsed/re...
Genelux reports interim data of systemic administration of Olvi-Vec
Genelux (GNLX) announced interim results from two ongoing trials – Phase 1b/2 SCLC and Phase 2 VIRO-25 – evaluating systemic administration of Olvi-Vec in patients with progressive small cell lung…
Genelux appoints Jason Litten as CMO
Genelux (GNLX) Corporation announced the appointment of Jason Litten as Chief Medical Officer, effective January 2. Dr. Litten will oversee all clinical development and medical strategy as the company...
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., a...
Genelux reports Q3 EPS (21c), consensus (21c)
“In the third quarter, we continued to progress Olvi-Vec’s development across multiple solid tumor indications, positioning the program for meaningful clinical milestones and key catalysts in the comi...
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --